User login
Key clinical point: Patients with psoriatic arthritis (PsA) who received risankizumab vs placebo were more likely to achieve clinically meaningful improvements in patient-reported outcomes (PRO).
Major finding: At week 24, patients receiving risankizumab vs placebo were significantly more likely to report minimal clinically important differences (MCID) in Patient’s Global Assessment of Disease Activity (PtGA) in both KEEPsAKE-1 (odds ratio [OR] 2.0; P < .001) and KEEPsAKE-2 (OR 1.9; P < .01) studies, with further improvement until week 52. Risankizumab significantly improved other PRO like pain, fatigue, quality of life, and physical functioning (P < .05).
Study details: The data come from an analysis of 2 phase 3 trials, KEEPsAKE-1 and KEEPsAKE-2, including adults with PsA and inadequate response or intolerance to disease-modifying antirheumatic drugs or biologics who were randomly assigned to receive risankizumab or placebo for 24 weeks and only risankizumab during weeks 24-52.
Disclosures: This study was funded by AbbVie. Three authors declared being employees or stockholders of AbbVie. The other authors reported ties with several sources, including AbbVie.
Source: Kristensen LE et al. The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: Results from KEEPsAKE 1 and 2. J Eur Acad Dermatol Venereol. 2022 (Aug 3). Doi: 10.1111/jdv.18475
Key clinical point: Patients with psoriatic arthritis (PsA) who received risankizumab vs placebo were more likely to achieve clinically meaningful improvements in patient-reported outcomes (PRO).
Major finding: At week 24, patients receiving risankizumab vs placebo were significantly more likely to report minimal clinically important differences (MCID) in Patient’s Global Assessment of Disease Activity (PtGA) in both KEEPsAKE-1 (odds ratio [OR] 2.0; P < .001) and KEEPsAKE-2 (OR 1.9; P < .01) studies, with further improvement until week 52. Risankizumab significantly improved other PRO like pain, fatigue, quality of life, and physical functioning (P < .05).
Study details: The data come from an analysis of 2 phase 3 trials, KEEPsAKE-1 and KEEPsAKE-2, including adults with PsA and inadequate response or intolerance to disease-modifying antirheumatic drugs or biologics who were randomly assigned to receive risankizumab or placebo for 24 weeks and only risankizumab during weeks 24-52.
Disclosures: This study was funded by AbbVie. Three authors declared being employees or stockholders of AbbVie. The other authors reported ties with several sources, including AbbVie.
Source: Kristensen LE et al. The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: Results from KEEPsAKE 1 and 2. J Eur Acad Dermatol Venereol. 2022 (Aug 3). Doi: 10.1111/jdv.18475
Key clinical point: Patients with psoriatic arthritis (PsA) who received risankizumab vs placebo were more likely to achieve clinically meaningful improvements in patient-reported outcomes (PRO).
Major finding: At week 24, patients receiving risankizumab vs placebo were significantly more likely to report minimal clinically important differences (MCID) in Patient’s Global Assessment of Disease Activity (PtGA) in both KEEPsAKE-1 (odds ratio [OR] 2.0; P < .001) and KEEPsAKE-2 (OR 1.9; P < .01) studies, with further improvement until week 52. Risankizumab significantly improved other PRO like pain, fatigue, quality of life, and physical functioning (P < .05).
Study details: The data come from an analysis of 2 phase 3 trials, KEEPsAKE-1 and KEEPsAKE-2, including adults with PsA and inadequate response or intolerance to disease-modifying antirheumatic drugs or biologics who were randomly assigned to receive risankizumab or placebo for 24 weeks and only risankizumab during weeks 24-52.
Disclosures: This study was funded by AbbVie. Three authors declared being employees or stockholders of AbbVie. The other authors reported ties with several sources, including AbbVie.
Source: Kristensen LE et al. The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: Results from KEEPsAKE 1 and 2. J Eur Acad Dermatol Venereol. 2022 (Aug 3). Doi: 10.1111/jdv.18475